Denali Therapeutics
Logotype for Denali Therapeutics Inc

Denali Therapeutics (DNLI) investor relations material

Denali Therapeutics Jefferies Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Denali Therapeutics Inc
Jefferies Global Healthcare Conference summary18 Nov, 2026

AVLAYAH launch and commercial outlook

  • AVLAYAH launched for Hunter syndrome; the U.S. population is ~500, with 375 eligible under the current pediatric label, and ~1,500 additional patients worldwide.

  • The launch has completed two successful quarters; the commercial goal is to become the market leader by treating new patients and capturing prevalent patients switching from current ERT.

  • U.S. annual cost for a 30-kg patient is ~$800,000, versus $500,000 for current ERT; adult label expansion and international access are important growth drivers.

  • The 2026 Q4 revenue guidance is $30M-$32M; revenue generation is expected to extend the operating runway.

  • COMPASS includes 65 patients in neurologic and somatic/peripheral cohorts; its two-year endpoint is due at end-2027, with readout expected in 2028.

Sanfilippo program

  • A Sanfilippo BLA filing is planned for 2027; the opportunity is considered similar to Hunter syndrome, though prevalence estimates are harder to establish.

  • Initial results in the first eight patients showed an average 80% reduction in CSF heparan sulfate; a subset normalized the biomarker, while higher anti-drug antibodies were seen in some patients.

  • The WORLD 2027 presentation is planned to include all 20 patients, including 12 treated at the intended marketed dose; the dataset will include CSF heparan sulfate and other biomarkers.

  • GM3 normalized in six of seven patients in an earlier dataset; the Phase III confirmatory study has begun and includes Bayley, with Vineland among key secondary endpoints.

  • Enrollment and study design are being considered in light of Ultragenyx’s gene therapy approval, with ongoing FDA engagement on alignment for the program.

FTD-GRN program

  • The progranulin replacement program targets FTD patients with granulin mutations, estimated at 6%-10% of the overall FTD population.

  • Treatment duration was extended from six to 12 months to improve the opportunity to assess proximal lysosomal biomarkers and distal neurofilament light chain, which can take time to change.

  • After reviewing the totality of study data, the team plans to discuss a potential accelerated approval pathway with the FDA; future program steps will depend on the data.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Denali Therapeutics earnings date

Logotype for Denali Therapeutics Inc
9th Annual Evercore ISI HealthCONx Conference1 Dec, 2026
Denali Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Denali Therapeutics earnings date

Logotype for Denali Therapeutics Inc
9th Annual Evercore ISI HealthCONx Conference1 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Denali Therapeutics Inc is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company researches and creates treatments targeting conditions such as Alzheimer's disease, Parkinson’s disease, and other disorders affecting the central nervous system. Denali Therapeutics operates within the healthcare and biotechnology sectors. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.